{"id":"gen-004-with-aluminum-hydroxide-adjuvant","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL1200706","moleculeType":"Small molecule","molecularWeight":"78.00"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"GEN-004 is designed to activate CD8+ T-cell responses against shared tumor-associated antigens (TAAs) present on multiple cancer types. The aluminum hydroxide adjuvant enhances the immunogenicity of the vaccine by promoting a stronger adaptive immune response. This approach aims to enable the body's immune system to identify and eliminate cancer cells expressing these antigens.","oneSentence":"GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:38:01.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (in combination with checkpoint inhibitors)"},{"name":"Other solid tumors expressing shared tumor-associated antigens"}]},"trialDetails":[{"nctId":"NCT02116998","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2014-09","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":98},{"nctId":"NCT01995617","phase":"PHASE1","title":"Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2013-11","conditions":"Streptococcus Pneumoniae","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":223,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GEN-004"],"phase":"phase_2","status":"active","brandName":"GEN-004 with Aluminum Hydroxide Adjuvant","genericName":"GEN-004 with Aluminum Hydroxide Adjuvant","companyName":"Genocea Biosciences, Inc.","companyId":"genocea-biosciences-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"GEN-004 is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack tumor-associated antigens expressed on cancer cells. Used for Melanoma (in combination with checkpoint inhibitors), Other solid tumors expressing shared tumor-associated antigens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}